Cure Alzheimer's Fund Cure Alzheimer's Fund

Evaluation of Sleep-EEG in Transgenic Mice

2017

PsychoGenics will carry out EEG readings of sleeping and awake ACE1 transgenic mice containing genetic variants identified by Genome-Wide Association Studies (GWAS) for their impact on Alzheimer’s disease risk. This research is being conducted in conjunction with Robert Vassar, Ph.D.’s project “Molecular and Cellular Mechanisms of ACE1 Variant in Alzheimer’s Disease.”

PsychoGenics Studies of Alternative Neurodegenerative Pathways Translational

Funding to Date

$27,500

Focus

Studies of Alternative Neurodegenerative Pathways, Translational

Researchers

PsychoGenics

Related Content:


Evaluating the Contribution of TDP-43 Dysfunction and Cryptic Mis-Splicing to Alzheimer’s Disease Pathogenesis Leonard Petrucelli 2024-10-31 Role of Psychosocial Stress in Alzheimer’s Disease Filip Swirski 2024-10-31 Pre-Clinical Testing of CDK4/6 Inhibitors as a Therapeutic Strategy in Alzheimer’s Disease Using Alzheimer’s Disease Tauopathy Mouse Model Peter Sicinski 2024-09-24 Dysregulation of Signaling on Post Synaptic Density Scaffolds in Alzheimer’s Disease Alexandra C. Newton 2024-07-29 Novel Artificial Intelligence (AI) Decodes Aging Neurons Andrew J. Holbrook Theodore Zwang 2024-07-23 2-Deoxyglucose and Its Analogs as Novel Therapeutics to Build Resilience to Alzheimer’s Disease Rajiv R. Ratan Theodore J. Lampidis 2024-07-23 The Role of Calcium Homeostasis in Axonal Spheroid Formation in Alzheimer’s Disease Jaime Grutzendler 2024-06-13 Brain Entry and Exit Consortium: Neuroinflammation at the Choroid Plexus in Alzheimer’s Disease Maria Lehtinen 2024-05-02